Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237553 | 0.80 | KDM4E (0.48) | KMT2AMEN1HPGDALDH1A1LMNA | |
| SCHEMBL6243692 | 0.79 | KDM4E (0.49) | KMT2AMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL6243192 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL4007623 | 0.78 | KCNA5 (0.53) | KMT2AMEN1ATMHPGDKCNA5 | |
| SCHEMBL7247599 | 0.77 | KMT2A (0.52) | KMT2AMEN1ATMHPGDKCNA5 | |
| SCHEMBL4003481 | 0.76 | TRPV1 (0.54) | KMT2AMEN1ATMHPGDKCNA5 | |
| SCHEMBL6236477 | 0.76 | ALDH1A1 (0.56) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4004685 | 0.74 | KMT2A (0.50) | KMT2AMEN1ATMHPGDKCNA5 | |
| SCHEMBL6242112 | 0.73 | KMT2A (0.49) | KMT2AMEN1ATMHPGDKCNA5 | |
| SCHEMBL23418945 | 0.71 | KMT2A (0.75) | KMT2AMEN1ATMHPGDKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | KMT2A 2169/4885MEN1 2828/4885ATM 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.